Massachusetts Eliminated GLP-1 Weight Loss Coverage
The state cut coverage for weight loss medications to address rising drug costs in the fiscal 2027 budget.
Updated on Oct. 1, 2026 in Weight Loss
Live Poll
Should states prioritize saving money by cutting insurance coverage for weight loss medications?
Massachusetts removed GLP-1 weight loss drug coverage for MassHealth and the Group Insurance Commission (GIC) programs during the fiscal 2027 budget process. The decision followed a directive from the Healey administration to reduce total spending amid significant budget pressures.
Why it matters
State officials targeted GLP-1 drugs to curb spiraling costs, while activists and lawmakers continue to push for the restoration of these benefits. The policy shift has ignited a debate over public health access for thousands of state employees and retirees.
The GIC serves over 460,000 public employees and retirees, with 22,000 members previously utilizing GLP-1 drugs for weight loss. The program faced a $120 million spending cut mandate despite receiving a $300 million emergency funding infusion.
The players
Healey administration
The current state executive leadership under Governor Maura Healey that directed agencies to cut spending to address budget pressures.
Group Insurance Commission
A state agency providing health insurance for over 460,000 public employees and retirees in Massachusetts.
Kiame Mahaniah
The Health and Human Services Secretary who expressed the expectation that coverage could be restored in the future.
Novo Nordisk
The pharmaceutical manufacturer responsible for producing the GLP-1 drugs Wegovy and Ozempic.
The details
The Group Insurance Commission board finalized the coverage removal in a divided vote, aiming to manage financial constraints after being instructed by the Healey administration to trim costs. While the state has cut benefits, Novo Nordisk plans to lower the list price of Ozempic and Wegovy to $675 starting Jan. 1.
Timeline
In February 2026, the Group Insurance Commission voted to end GLP-1 drug coverage.
The removal of coverage was included in the fiscal 2027 state budget.
Novo Nordisk will implement a $675 list price for Wegovy and Ozempic on January 1, 2027.
Health Landscape
This coverage elimination follows a broader trend of state-level cost-containment measures directed by the Massachusetts fiscal 2027 budget. The move highlights the tension between rising demand for specialized weight loss treatments and the fiscal constraints faced by public insurance providers.
Public employees and retirees who previously relied on state-sponsored coverage for GLP-1 drugs must now seek alternative payment methods or face higher out-of-pocket costs for their treatments. These residents should review their specific benefit plans to understand how the changes affect their individual medical access.
The takeaway
The move reflects the ongoing fiscal challenge of balancing expensive, newer pharmaceutical treatments within limited public health budgets. Residents are encouraged to monitor state legislative updates, as local officials have indicated that coverage may be reassessed in future cycles.
Further reading
Explore ongoing Weight Loss trends and medical policy shifts across the state.
Live Poll
Should states prioritize saving money by cutting insurance coverage for weight loss medications?
